- Lung cancer therapy including novel compounds and early phase trials
- Breast cancer therapeutics including novel compounds and early phase trials
- Health services research
- Economics of lung cancer therapy
- Treatment decision-making in advanced cancer, including development of patient decision aids
- Patient-physician communication
Natasha B Leighl
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
Oncologist. 2016 Aug 17;
A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer.
Clin Lung Cancer. 2016 Jul 9;
Oncologist. 2016 Jul 22;
Curr Oncol. 2016 Jun;23(3):178-83
How do women trade-off benefits and risks in chemotherapy treatment decisions based on gene expression profiling for early-stage breast cancer? A discrete choice experiment.
BMJ Open. 2016;6(6):e010981
176P: ALK-rearranged non-small cell lung cancer is associated with a high rate of venous thromboembolism.
J Thorac Oncol. 2016 Apr;11(4 Suppl):S134
The influence of gene expression profiling on decisional conflict in decision making for early-stage breast cancer chemotherapy.
Eur J Cancer. 2016 May 4;61:85-93
CMAJ. 2016 Apr 18;
A window of opportunity study of potential tumor and soluble biomarkers of response to preoperative erlotinib in early stage non-small cell lung cancer.
Oncotarget. 2016 Mar 25;
The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.
Cancer Treat Rev. 2016 Mar 15;45:139-162
Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
President, Lung Cancer Canada
Chair, Working Group on Economic Analysis, National Cancer Institute of Canada Clinical Trials Group